Benzinga | Nov 9, 2020 08:16AM EST

UroGen Pharma Q3 EPS $(1.31) Beats $(1.49) Estimate, Sales $3.46M Beat $3.34M Estimate

UroGen Pharma (NASDAQ:URGN) reported quarterly losses of $(1.31) per share which beat the analyst consensus estimate of $(1.49) by 12.08 percent. This is a 23.58 percent decrease over losses of $(1.06) per share from the same period last year. The company reported quarterly sales of $3.46 million which beat the analyst consensus estimate of $3.34 million by 3.62 percent.